Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 11;13:1333–1342. doi: 10.2147/CMAR.S274631

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Tian et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Apatinib inhibits the ELOVL6 expression in HCT116 cells. (A) The GEPIA database (http://gepia.cancer-pku.cn/) displayed that ELOVL6 is highly expressed in CRC tissues compared with the normal tissues. The expression of ELOVL6 in HCT116 and HIEC cells was detected using (B) Western blot analysis and (C) RT-qPCR, respectively. ***P<0.001 vs HIEC. (D) RT-qPCR and (E) Western blot analyses (40 μg protein sample per lane) were employed to evaluate the level of ELOVL6 after treatment of apatinib. *P<0.05, **P<0.01 and ***P<0.001 vs control.

Abbreviations: ELOVL6, elongation of very long-chain fatty acids family member 6; CRC, colorectal cancer.